| Bioactivity | Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research[1][2]. | ||||||
| Invitro | Angiopeptin (0.1 nM- 10 μM; for 1 h) TFA acts as a partial agonist (pEC50=6.57) with a maximum response of 423% at 3 μM on the release of tritium on CHO hsst2 cells[2]. | ||||||
| Name | Angiopeptin TFA | ||||||
| CAS | 2478421-60-0 | ||||||
| Shortening | {Nal}CYWKVCT-NH2 | ||||||
| Formula | C58H73F6N11O14S2 | ||||||
| Molar Mass | 1326.39 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Angiopeptin TFA
CAS: 2478421-60-0 F: C58H73F6N11O14S2 W: 1326.39
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 v
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.